A Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Investigate the Efficacy and Safety of Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC Study)

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Investigate the Efficacy and Safety of Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC Study)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 25 May 2017

At a glance

  • Drugs Fedovapagon (Primary)
  • Indications Nocturia
  • Focus Therapeutic Use
  • Acronyms EQUINOC
  • Sponsors Vantia Therapeutics
  • Most Recent Events

    • 19 May 2017 Planned End Date changed from 1 Mar 2017 to 1 Aug 2017.
    • 19 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jul 2017.
    • 19 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top